Several analysts have recently updated their ratings and price targets for 908 Devices (NASDAQ: MASS):
- 8/12/2026 – 908 Devices had its price target raised by Stifel Nicolaus from $10.00 to $12.00. They now have a “buy” rating on the stock.
- 8/12/2026 – 908 Devices had its price target raised by Roth Capital from $11.00 to $13.00. They now have a “buy” rating on the stock.
- 8/7/2026 – 908 Devices had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 7/29/2026 – 908 Devices is now covered by Roth Capital. They set a “buy” rating and a $11.00 price target on the stock.
- 7/29/2026 – 908 Devices is now covered by Roth Capital. They set a “buy” rating and a $11.00 price target on the stock.
- 7/18/2026 – 908 Devices was downgraded by Wall Street Zen from “buy” to “hold”.
- 6/27/2026 – 908 Devices was upgraded by Wall Street Zen from “hold” to “buy”.
Insiders Place Their Bets
In other 908 Devices news, CFO Joseph H. Iv Griffith sold 6,940 shares of 908 Devices stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $9.03, for a total value of $62,668.20. Following the completion of the sale, the chief financial officer owned 132,956 shares in the company, valued at $1,200,592.68. The trade was a 4.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher D. Brown sold 8,358 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $9.23, for a total transaction of $77,144.34. Following the transaction, the director directly owned 805,559 shares in the company, valued at approximately $7,435,309.57. This represents a 1.03% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 106,940 shares of company stock valued at $949,714. Company insiders own 28.20% of the company’s stock.
Key products in 908 Devices’ portfolio include the MX908, a handheld high-resolution mass spectrometer capable of detecting and identifying a broad range of chemicals and explosives; the M908 portable mass spectrometer for laboratory or mobile units; and the ZipChip capillary electrophoresis system for high-throughput, microfluidic separations.
See Also
- Five stocks we like better than 908 Devices
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for 908 Devices Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 908 Devices Inc and related companies with MarketBeat.com's FREE daily email newsletter.
